National Cancer Institute National Cancer Institute
U.S. National Institutes of Health National Cancer Institute
NCI Home Cancer Topics Clinical Trials Cancer Statistics Research & Funding News About NCI
Wilms Tumor and Other Childhood Kidney Tumors Treatment (PDQ®)
Patient VersionHealth Professional VersionEn españolLast Modified: 11/07/2008
Table 1. Standard Chemotherapy Regimens for Wilms Tumor

Regimen Name  Regimen Description 
Regimen EE-4A [1] vincristine, dactinomycin x 18 weeks post-nephrectomy
Regimen DD-4A [1] vincristine, dactinomycin, doxorubicin x 24 weeks post nephrectomy
Regimen I [2] vincristine, doxorubicin, cyclophosphamide, etoposide x 24 weeks

References

  1. Green DM, Breslow NE, Beckwith JB, et al.: Comparison between single-dose and divided-dose administration of dactinomycin and doxorubicin for patients with Wilms' tumor: a report from the National Wilms' Tumor Study Group. J Clin Oncol 16 (1): 237-45, 1998.  [PUBMED Abstract]

  2. Dome JS, Cotton CA, Perlman EJ, et al.: Treatment of anaplastic histology Wilms' tumor: results from the fifth National Wilms' Tumor Study. J Clin Oncol 24 (15): 2352-8, 2006.  [PUBMED Abstract]


A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov